Review



naive cd4 t cell isolation kit  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Miltenyi Biotec naive cd4 t cell isolation kit
    Naive Cd4 T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 993 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45+cells/CD45+MicroBeads%2C+mouse/pm42810339-272-40-36
    Average 97 stars, based on 993 article reviews
    naive cd4 t cell isolation kit - by Bioz Stars, 2026-11
    97/100 stars

    Images

    Related Articles

    Labeling:

    Article Title: Mechanistic insights into cordycepin-enhanced CTLA-4 blockade efficacy via Eubacterium rectale-mediated immunomodulation in colon cancer.
    Article Snippet: The tissues were dissociated using the Tissue Dissociation Kit A Pro (SeekGene, K01801-30). .. CD45+ cells were labeled and enriched using CD45 MicroBeads (Miltenyi, 130-052-301) and resuspended in RPMI 1640 medium containing 2% FBS to a concentration of 1 × 106 cells/mL. ..


    Concentration Assay:

    Article Title: Mechanistic insights into cordycepin-enhanced CTLA-4 blockade efficacy via Eubacterium rectale-mediated immunomodulation in colon cancer.
    Article Snippet: The tissues were dissociated using the Tissue Dissociation Kit A Pro (SeekGene, K01801-30). .. CD45+ cells were labeled and enriched using CD45 MicroBeads (Miltenyi, 130-052-301) and resuspended in RPMI 1640 medium containing 2% FBS to a concentration of 1 × 106 cells/mL. ..

    Incubation:

    Article Title: Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon.
    Article Snippet: .. To positively isolate the CD45+ cells in tumor samples, 20μl CD45 MicroBeads (130-052-301, Miltenyi Biotec) were added to each sample and followed with an incubation for 15 mins at 4◦C. .. Subsequently, the cell suspensions were applied onto the LS magnetic columns (130-042-401, Miltenyi Biotec) to positively select immune cells in the samples according to the manufacturer’s instructions.

    Article Title: Pericytes are organ-specific regulators of tissue morphogenesis
    Article Snippet: Cells were centrifuged for 5 min at 4 °C, and the pellet was resuspended in cold MACS depletion buffer (autoMACS Running Buffer-MACS Separation Buffer, Miltenyi Biotec, 130-091-221). .. To proceed with magnetic separation and depletion of CD45+ cells and erythrocytes from the cell suspension, CD45 microbeads (Miltenyi Biotec, 130-052-301) and Ter119 microbeads (Miltenyi Biotec, 130-049-901) were added to the cells resuspended in MACS depletion buffer and incubated for 20 min at 4 °C. .. After washing, the cell solutions were passed through the MACS MS column (Miltenyi Biotec, 130-042-201) attached to a MACS separator placed on a magnetic Multistand.

    Suspension:

    Article Title: Pericytes are organ-specific regulators of tissue morphogenesis
    Article Snippet: Cells were centrifuged for 5 min at 4 °C, and the pellet was resuspended in cold MACS depletion buffer (autoMACS Running Buffer-MACS Separation Buffer, Miltenyi Biotec, 130-091-221). .. To proceed with magnetic separation and depletion of CD45+ cells and erythrocytes from the cell suspension, CD45 microbeads (Miltenyi Biotec, 130-052-301) and Ter119 microbeads (Miltenyi Biotec, 130-049-901) were added to the cells resuspended in MACS depletion buffer and incubated for 20 min at 4 °C. .. After washing, the cell solutions were passed through the MACS MS column (Miltenyi Biotec, 130-042-201) attached to a MACS separator placed on a magnetic Multistand.

    Magnetic Cell Separation:

    Article Title: Pericytes are organ-specific regulators of tissue morphogenesis
    Article Snippet: Cells were centrifuged for 5 min at 4 °C, and the pellet was resuspended in cold MACS depletion buffer (autoMACS Running Buffer-MACS Separation Buffer, Miltenyi Biotec, 130-091-221). .. To proceed with magnetic separation and depletion of CD45+ cells and erythrocytes from the cell suspension, CD45 microbeads (Miltenyi Biotec, 130-052-301) and Ter119 microbeads (Miltenyi Biotec, 130-049-901) were added to the cells resuspended in MACS depletion buffer and incubated for 20 min at 4 °C. .. After washing, the cell solutions were passed through the MACS MS column (Miltenyi Biotec, 130-042-201) attached to a MACS separator placed on a magnetic Multistand.

    other:

    Article Title: Cytoarchitectural multi-depot profiling reveals immune-metabolic crosstalk in human colon-associated adipose tissue
    Article Snippet: Briefly, adipose tissue was minced and enzymatically digested for 30 min at 37° C in supplemented KnockOut DMEM (10829018, Thermo Fisher Scientific) containing penicillin/streptomycin (15140122), Antibiotic-Antimycotic (15240062), 1 mM sodium pyruvate (11360070), 1× MEM non-essential amino acids (11140050), 2 mM L-glutamine (25030024), 1× Endothelial Cell Growth Factor supplements (ECGS/heparin; C-30120, PromoCell), collagenase I (17100017), 0.25 U/mL Dispase, and 7.5 mg/mL DNase I.

    Isolation:

    Article Title: Bioengineered anti-EpCAM-guided exosome nanocarriers delivering Foxp3 agonist butyrate achieve tissue-specific immunomodulation in autoimmune Sjögren's syndrome.
    Article Snippet: .. CD45+ cells were first isolated with CD45 MicroBeads (Miltenyi, 130-052-301), and the remaining supernatant was enriched for ECs using EpCAM MicroBeads (Miltenyi, 130-105-958). .. Refined sorting was performed on a BD FACSAria III (BD Biosciences) using anti-CD45-APC (BD, 559864) and anti-EpCAM-FITC (BioLegend, 118206).



    Similar Products

    99
    Sony Biotechnology viable cd45 7 aad immune cells
    Viable Cd45 7 Aad Immune Cells, supplied by Sony Biotechnology, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45+cells/MA900+Multi-Application+Sorter/pmc13647478-176-1-16
    Average 99 stars, based on 1 article reviews
    viable cd45 7 aad immune cells - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec naive cd4 t cell isolation kit
    Naive Cd4 T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45+cells/CD45+MicroBeads%2C+mouse/pm42810339-272-40-36
    Average 97 stars, based on 1 article reviews
    naive cd4 t cell isolation kit - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec magnetic bead cell separation system
    Magnetic Bead Cell Separation System, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45+cells/CD45+MicroBeads%2C+human/10__1038_slash_s42003___026___10868___8-244-21-20
    Average 96 stars, based on 1 article reviews
    magnetic bead cell separation system - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec cd45 cells
    Cd45 Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45+cells/CD45+MicroBeads%2C+mouse/pm42392076-1039-4-14
    Average 97 stars, based on 1 article reviews
    cd45 cells - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd45 positive cells
    (A) Representative images (left panel) and quantification (right panel) of p16 + cancer cells in treatment-naive (n=17) and gemcitabine/cisplatin (Gem/Cis)-treated (n=22) human CCA. (B) Telomere-associated foci (γH2AX immunofluorescence with telomere fluorescence in situ hybridization) (left panel) and quantification (right panel) in p16 + cancer cells. (C-E) Sequential immunofluorescence quantifying p16 + cancer cells (KRT19 + ), cancer-associated fibroblasts (α-SMA + ), and immune cells <t>(CD45</t> + ), and the proliferative status (Ki67) of p16 + cells. (F) Senescence-associated β-galactosidase activity in human RBE CCA cells, proliferating versus doxorubicin or Gem/Cis-induced. (G) Single-nucleus RNA sequencing of human CCA (n=10 patients): UMAP of cell populations and expression of CDKN2A , CDKN1A , and MKI67 with senescence (SenMayo, Fridman, and Reactome cellular senescence) gene-set scores. (H) Multivariable Cox regression of senescence transcriptional scores and overall survival, adjusted for age, sex, and stage, performed independently in the Mayo discovery cohort (n=158, 108 events) and an external Asian cohort (OEP00105, n=244, 99 events). White arrows, senescent-like cancer cells. Scale bar, 50 µm. Data are mean ± SEM; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, not significant.
    Cd45 Positive Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45+cells/CD45+(TIL)+MicroBeads%2C+mouse/bio_rxiv__64898__2026__06__24__734341-213-0-10
    Average 96 stars, based on 1 article reviews
    cd45 positive cells - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd45 ter119 cd31 lepr mscs
    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of <t>CD45</t> − <t>Ter119</t> − <t>CD31</t> hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
    Cd45 Ter119 Cd31 Lepr Mscs, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45+cells/Erythroid+Cells+Antibody%2C+anti-rat%2C+REAfinity/pmc12859453-534-18-35
    Average 96 stars, based on 1 article reviews
    cd45 ter119 cd31 lepr mscs - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec single cell suspensions
    (A) Workflow illustrating circadian phase inference and rhythmic gene identification in human <t>TNBC</t> <t>single-cell</t> RNA-seq data using CYCLOPS2.0 and DiscoRhythm. (B) Left: Stacked bar plots showing relative proportions of immune cell populations across predicted circadian phases within the human TNBC tumor microenvironment (TME). Right: Line plots showing circadian fitting curves of myeloid (top) and CD8⁺ T cell (bottom) fractions across a circadian day. Points indicate mean values at each time point (± SEM). Gray shading denotes the dark phase (CT12–CT24/CT0). p values indicate rhythmicity assessed by cosinor regression. n = 10-13 patient samples per time point. (C) Heatmap showing rhythmic expression patterns of circadian genes in CD4⁺ T cells across inferred circadian phases. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (D) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in CD4⁺ T cells, including interferon signaling and T cell activation. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (E) Circadian fitting curves of representative genes ( STAT3 and BCL6 ) in CD4⁺ T cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (F) Heatmap showing rhythmic expression patterns of circadian genes in CD8⁺ T cells across inferred circadian time points. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (G) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in CD8⁺ T cells, including interferon signaling and T cell activation. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (H) Circadian fitting curves of representative genes ( STAT3 and BCL6 ) in CD8⁺ T cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (I) Heatmap showing rhythmic expression patterns of circadian genes in myeloid cells across inferred circadian time points. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (J) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in myeloid cells, including regulation of phagocytosis and type II interferon signaling. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (K) Circadian fitting curves of representative genes ( SYK and STAT1 ) in myeloid cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (L) Circadian fitting curves illustrating the temporal mismatch between antigen processing and presentation in myeloid cells and T cell recognition programs in CD4⁺ and CD8⁺ T cells. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile). Vertical dashed lines indicate the peak timing of each functional program. The gray area indicates the dark phase (CT12–CT24/CT0). (M) Circadian expression profiles of representative genes involved in antigen presentation ( CIITA , HLA-A ) in myeloid cells and T cell recognition ( CD3D , TRAV35 ) in CD4⁺ and CD8⁺ T cells. Points represent mean expression values at each inferred circadian time point, with error bars indicating SEM. The gray area indicates the dark phase (CT12–CT24/CT0).
    Single Cell Suspensions, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45+cells/CD45+MicroBeads%2C+mouse/bio_rxiv__64898__2026__05__26__726543-247-5-12
    Average 97 stars, based on 1 article reviews
    single cell suspensions - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    94
    Multi Sciences (Lianke) Biotech Co Ltd cd8 t cells
    (A) Workflow illustrating circadian phase inference and rhythmic gene identification in human <t>TNBC</t> <t>single-cell</t> RNA-seq data using CYCLOPS2.0 and DiscoRhythm. (B) Left: Stacked bar plots showing relative proportions of immune cell populations across predicted circadian phases within the human TNBC tumor microenvironment (TME). Right: Line plots showing circadian fitting curves of myeloid (top) and CD8⁺ T cell (bottom) fractions across a circadian day. Points indicate mean values at each time point (± SEM). Gray shading denotes the dark phase (CT12–CT24/CT0). p values indicate rhythmicity assessed by cosinor regression. n = 10-13 patient samples per time point. (C) Heatmap showing rhythmic expression patterns of circadian genes in CD4⁺ T cells across inferred circadian phases. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (D) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in CD4⁺ T cells, including interferon signaling and T cell activation. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (E) Circadian fitting curves of representative genes ( STAT3 and BCL6 ) in CD4⁺ T cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (F) Heatmap showing rhythmic expression patterns of circadian genes in CD8⁺ T cells across inferred circadian time points. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (G) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in CD8⁺ T cells, including interferon signaling and T cell activation. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (H) Circadian fitting curves of representative genes ( STAT3 and BCL6 ) in CD8⁺ T cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (I) Heatmap showing rhythmic expression patterns of circadian genes in myeloid cells across inferred circadian time points. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (J) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in myeloid cells, including regulation of phagocytosis and type II interferon signaling. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (K) Circadian fitting curves of representative genes ( SYK and STAT1 ) in myeloid cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (L) Circadian fitting curves illustrating the temporal mismatch between antigen processing and presentation in myeloid cells and T cell recognition programs in CD4⁺ and CD8⁺ T cells. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile). Vertical dashed lines indicate the peak timing of each functional program. The gray area indicates the dark phase (CT12–CT24/CT0). (M) Circadian expression profiles of representative genes involved in antigen presentation ( CIITA , HLA-A ) in myeloid cells and T cell recognition ( CD3D , TRAV35 ) in CD4⁺ and CD8⁺ T cells. Points represent mean expression values at each inferred circadian time point, with error bars indicating SEM. The gray area indicates the dark phase (CT12–CT24/CT0).
    Cd8 T Cells, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45+cells/Anti-Human+CD45/10__3389_slash_fimmu__2026__1722661-89-6-18
    Average 94 stars, based on 1 article reviews
    cd8 t cells - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    (A) Representative images (left panel) and quantification (right panel) of p16 + cancer cells in treatment-naive (n=17) and gemcitabine/cisplatin (Gem/Cis)-treated (n=22) human CCA. (B) Telomere-associated foci (γH2AX immunofluorescence with telomere fluorescence in situ hybridization) (left panel) and quantification (right panel) in p16 + cancer cells. (C-E) Sequential immunofluorescence quantifying p16 + cancer cells (KRT19 + ), cancer-associated fibroblasts (α-SMA + ), and immune cells (CD45 + ), and the proliferative status (Ki67) of p16 + cells. (F) Senescence-associated β-galactosidase activity in human RBE CCA cells, proliferating versus doxorubicin or Gem/Cis-induced. (G) Single-nucleus RNA sequencing of human CCA (n=10 patients): UMAP of cell populations and expression of CDKN2A , CDKN1A , and MKI67 with senescence (SenMayo, Fridman, and Reactome cellular senescence) gene-set scores. (H) Multivariable Cox regression of senescence transcriptional scores and overall survival, adjusted for age, sex, and stage, performed independently in the Mayo discovery cohort (n=158, 108 events) and an external Asian cohort (OEP00105, n=244, 99 events). White arrows, senescent-like cancer cells. Scale bar, 50 µm. Data are mean ± SEM; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, not significant.

    Journal: bioRxiv

    Article Title: Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinoma

    doi: 10.64898/2026.06.24.734341

    Figure Lengend Snippet: (A) Representative images (left panel) and quantification (right panel) of p16 + cancer cells in treatment-naive (n=17) and gemcitabine/cisplatin (Gem/Cis)-treated (n=22) human CCA. (B) Telomere-associated foci (γH2AX immunofluorescence with telomere fluorescence in situ hybridization) (left panel) and quantification (right panel) in p16 + cancer cells. (C-E) Sequential immunofluorescence quantifying p16 + cancer cells (KRT19 + ), cancer-associated fibroblasts (α-SMA + ), and immune cells (CD45 + ), and the proliferative status (Ki67) of p16 + cells. (F) Senescence-associated β-galactosidase activity in human RBE CCA cells, proliferating versus doxorubicin or Gem/Cis-induced. (G) Single-nucleus RNA sequencing of human CCA (n=10 patients): UMAP of cell populations and expression of CDKN2A , CDKN1A , and MKI67 with senescence (SenMayo, Fridman, and Reactome cellular senescence) gene-set scores. (H) Multivariable Cox regression of senescence transcriptional scores and overall survival, adjusted for age, sex, and stage, performed independently in the Mayo discovery cohort (n=158, 108 events) and an external Asian cohort (OEP00105, n=244, 99 events). White arrows, senescent-like cancer cells. Scale bar, 50 µm. Data are mean ± SEM; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, not significant.

    Article Snippet: CD45 positive cells were enriched with CD45 (TIL) MicroBeads, mouse (Miltenyi # 130-110-618) according to the manufacturer’s instruction.

    Techniques: Immunofluorescence, Fluorescence, In Situ Hybridization, Activity Assay, RNA Sequencing, Expressing

    (A) p21 + cancer cells in treatment-naive (n=15) versus Gem/Cis-treated (n=19) human CCA. (B-D) Sequential immunofluorescence of p21 + cancer cells (KRT19 + ), cancer-associated fibroblasts (α-SMA + ), and immune cells (CD45 + ), and Ki67 status. (E-F) Senescence induction in SB1 cells with alisertib (0.2 µM, Aurora kinase A inhibitor) or etoposide (0.5 µM, topoisomerase II inhibitor) over 6 days, with drug withdrawn at day 4, confirmed by SA-β-gal and (E) p21 immunostaining (F).

    Journal: bioRxiv

    Article Title: Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinoma

    doi: 10.64898/2026.06.24.734341

    Figure Lengend Snippet: (A) p21 + cancer cells in treatment-naive (n=15) versus Gem/Cis-treated (n=19) human CCA. (B-D) Sequential immunofluorescence of p21 + cancer cells (KRT19 + ), cancer-associated fibroblasts (α-SMA + ), and immune cells (CD45 + ), and Ki67 status. (E-F) Senescence induction in SB1 cells with alisertib (0.2 µM, Aurora kinase A inhibitor) or etoposide (0.5 µM, topoisomerase II inhibitor) over 6 days, with drug withdrawn at day 4, confirmed by SA-β-gal and (E) p21 immunostaining (F).

    Article Snippet: CD45 positive cells were enriched with CD45 (TIL) MicroBeads, mouse (Miltenyi # 130-110-618) according to the manufacturer’s instruction.

    Techniques: Immunofluorescence, Immunostaining

    (A) SB1 p21-ATTAC in vivo study schematic. (B) Representative gross images and tumor-burden quantification, vehicle versus AP-treated SB1 p21-ATTAC tumors. (C) Relative mRNA of p21-promoter tGFP reporter in veh and AP treated murine SB1 p21-ATTAC tumors. (D) p21 mean fluorescence intensity in veh and AP treated murine SB1 p21-ATTAC tumors. Scale bar, 100 µm. (E) Body weights of SB1 p16-ATTAC tumor bearing mice treated with or AP. (F) Monocytic myeloid-derived suppressor cell (M-MDSC), polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC), regulatory T-cell (Treg), CD4 + T cells, and natural killer (NK) frequencies (% of CD45 + cells) in in SB1 p16-ATTAC tumors. (G) M1 macrophage, TAM, CD8 + CTL, granzyme B + CD8 + CTL frequencies in SB1 p21-ATTAC tumors. (H) Body weights of SB1 p21-ATTAC tumor bearing mice treated with or AP. (I) M-MDSC, PMN-MDSC, Treg, CD4 + T-cell, and NK-cell frequencies in SB1 p21-ATTAC tumors. Data are mean ± SEM; *, P<0.05; **, P<0.01.

    Journal: bioRxiv

    Article Title: Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinoma

    doi: 10.64898/2026.06.24.734341

    Figure Lengend Snippet: (A) SB1 p21-ATTAC in vivo study schematic. (B) Representative gross images and tumor-burden quantification, vehicle versus AP-treated SB1 p21-ATTAC tumors. (C) Relative mRNA of p21-promoter tGFP reporter in veh and AP treated murine SB1 p21-ATTAC tumors. (D) p21 mean fluorescence intensity in veh and AP treated murine SB1 p21-ATTAC tumors. Scale bar, 100 µm. (E) Body weights of SB1 p16-ATTAC tumor bearing mice treated with or AP. (F) Monocytic myeloid-derived suppressor cell (M-MDSC), polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC), regulatory T-cell (Treg), CD4 + T cells, and natural killer (NK) frequencies (% of CD45 + cells) in in SB1 p16-ATTAC tumors. (G) M1 macrophage, TAM, CD8 + CTL, granzyme B + CD8 + CTL frequencies in SB1 p21-ATTAC tumors. (H) Body weights of SB1 p21-ATTAC tumor bearing mice treated with or AP. (I) M-MDSC, PMN-MDSC, Treg, CD4 + T-cell, and NK-cell frequencies in SB1 p21-ATTAC tumors. Data are mean ± SEM; *, P<0.05; **, P<0.01.

    Article Snippet: CD45 positive cells were enriched with CD45 (TIL) MicroBeads, mouse (Miltenyi # 130-110-618) according to the manufacturer’s instruction.

    Techniques: In Vivo, Fluorescence, Derivative Assay

    (A) Schema depicting in vivo study. SB tumor-bearing mice were treated for 2 weeks with vehicle, alisertib or etoposide. (B) Frequencies of M1 macrophages and M2-like tumor-associated macrophages (TAMs) (% of CD45 + cells) by flow cytometry. (C) Schematic of macrophage education; senescent-like state induced by alisertib or etoposide. (D) Bone-marrow-derived macrophage (BMDM) viability after conditioned medium from proliferating versus senescent-like cells. (E) Proliferation of CFSE-labeled CD8 + T cells co-cultured with educated BMDMs. Data are mean ± SEM; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, not significant.

    Journal: bioRxiv

    Article Title: Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinoma

    doi: 10.64898/2026.06.24.734341

    Figure Lengend Snippet: (A) Schema depicting in vivo study. SB tumor-bearing mice were treated for 2 weeks with vehicle, alisertib or etoposide. (B) Frequencies of M1 macrophages and M2-like tumor-associated macrophages (TAMs) (% of CD45 + cells) by flow cytometry. (C) Schematic of macrophage education; senescent-like state induced by alisertib or etoposide. (D) Bone-marrow-derived macrophage (BMDM) viability after conditioned medium from proliferating versus senescent-like cells. (E) Proliferation of CFSE-labeled CD8 + T cells co-cultured with educated BMDMs. Data are mean ± SEM; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, not significant.

    Article Snippet: CD45 positive cells were enriched with CD45 (TIL) MicroBeads, mouse (Miltenyi # 130-110-618) according to the manufacturer’s instruction.

    Techniques: In Vivo, Flow Cytometry, Derivative Assay, Labeling, Cell Culture

    (A) M-MDSC, PMN-MDSC, and regulatory T-cell (Treg) frequencies (% of CD45 + cells) in the SB1 tumor bearing mice treated with vehicle, alisertib, or etoposide. (B) Schematic of subcutaneous tumor model study. (C) M1 macrophage, TAM, M-MDSC, PMN-MDSC, Treg frequencies in subcutaneous SB1 tumor bearing mice treated with vehicle, alisertib, or etoposide. Data are mean ± SEM; *, P<0.05; **; ns, not significant.

    Journal: bioRxiv

    Article Title: Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinoma

    doi: 10.64898/2026.06.24.734341

    Figure Lengend Snippet: (A) M-MDSC, PMN-MDSC, and regulatory T-cell (Treg) frequencies (% of CD45 + cells) in the SB1 tumor bearing mice treated with vehicle, alisertib, or etoposide. (B) Schematic of subcutaneous tumor model study. (C) M1 macrophage, TAM, M-MDSC, PMN-MDSC, Treg frequencies in subcutaneous SB1 tumor bearing mice treated with vehicle, alisertib, or etoposide. Data are mean ± SEM; *, P<0.05; **; ns, not significant.

    Article Snippet: CD45 positive cells were enriched with CD45 (TIL) MicroBeads, mouse (Miltenyi # 130-110-618) according to the manufacturer’s instruction.

    Techniques:

    (A) Strategy for p16-promoter-restricted Gdf15 silencing (shRNA) and Gdf15 overexpression in orthotopic SB1 CCA. (B) Representative gross images (left) and tumor/liver weight quantification (right). (C-D) TAM and CD8 + CTL frequencies (% of CD45 + cells) in p16-shCtrl , SB-p16-shGdf15, and SB- p16-Gdf15 OE tumors via flow cytometry. (E) (A) EpCAM⁺GDF-15⁺ CCA cells (teal) adjacent to TAMs (pink); EpCAM⁺ (blue) and GDF-15⁺ (orange) transcripts shown. Scale bar 100 µm. (B) Per-TAM immunosuppressive score (per-sample z) versus distance to the nearest GDF-15⁺ or GDF-15⁻ CCA cell (TAMs ≤200 µm; n = 13,597 and 14,703 across three iCCA samples). Line/band: linear fit ± 95% CI; β and P from linear mixed-effects [score ∼ distance + (1|sample)]. The gradient is GDF-15⁺-specific (β = −3.79×10⁻³/µm, P < 10⁻¹⁰) and absent for GDF-15⁻ cells (β = +9.11×10⁻⁴/µm, P = 0.004). Scale bar, 100 µm. Data are mean ± SEM; *, P<0.05; ***, P<0.001; ns, not significant.

    Journal: bioRxiv

    Article Title: Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinoma

    doi: 10.64898/2026.06.24.734341

    Figure Lengend Snippet: (A) Strategy for p16-promoter-restricted Gdf15 silencing (shRNA) and Gdf15 overexpression in orthotopic SB1 CCA. (B) Representative gross images (left) and tumor/liver weight quantification (right). (C-D) TAM and CD8 + CTL frequencies (% of CD45 + cells) in p16-shCtrl , SB-p16-shGdf15, and SB- p16-Gdf15 OE tumors via flow cytometry. (E) (A) EpCAM⁺GDF-15⁺ CCA cells (teal) adjacent to TAMs (pink); EpCAM⁺ (blue) and GDF-15⁺ (orange) transcripts shown. Scale bar 100 µm. (B) Per-TAM immunosuppressive score (per-sample z) versus distance to the nearest GDF-15⁺ or GDF-15⁻ CCA cell (TAMs ≤200 µm; n = 13,597 and 14,703 across three iCCA samples). Line/band: linear fit ± 95% CI; β and P from linear mixed-effects [score ∼ distance + (1|sample)]. The gradient is GDF-15⁺-specific (β = −3.79×10⁻³/µm, P < 10⁻¹⁰) and absent for GDF-15⁻ cells (β = +9.11×10⁻⁴/µm, P = 0.004). Scale bar, 100 µm. Data are mean ± SEM; *, P<0.05; ***, P<0.001; ns, not significant.

    Article Snippet: CD45 positive cells were enriched with CD45 (TIL) MicroBeads, mouse (Miltenyi # 130-110-618) according to the manufacturer’s instruction.

    Techniques: shRNA, Over Expression, Flow Cytometry

    Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).

    Journal: Bioactive Materials

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    doi: 10.1016/j.bioactmat.2025.11.039

    Figure Lengend Snippet: Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).

    Article Snippet: Following washing with buffer, cells were incubated with APC streptavidin at 4 °C for 40 min. After washing, CD45 − Ter119 − CD31 − LepR + MSCs were sorted using the MACSQuant® Tyto® cell sorter (Miltenyi Biotec).

    Techniques: Staining, Immunofluorescence, Flow Cytometry, Micro-CT, Enzyme-linked Immunosorbent Assay

    SCS attenuates full-blown bone marrow senescence during GC-induced skeletal degeneration. ( A ) Schematic illustration of the experimental design for assessing bone marrow senescence at 4 weeks after combined SCS and MPS treatment. ( B ) Representative images of SA-β-Gal–positive cells (green) in femur after MPS treatment. BM indicates bone marrow; TBM indicates trabecular bone matrix. (Scale bars, 100 μm and 25 μm) ( C – E ) Representative immunofluorescence images at week 4 showing Emcn + sinusoidal ECs, ALP + osteoblasts, and p16 + senescent cells (C), with corresponding quantification of Emcn + p16 + (D) and ALP + p16 + cells (E). n = 6 biological replicates. (Scale bars, 100 μm and 50 μm) ( F – H ) Flow cytometry analysis of CD45 − Ter119 − CD31 + arteriolar ECs in the femur after PBS or SCS treatment (F). Ki-67 + proliferative status was further analyzed within this population (G), and corresponding double-positive cell quantification is shown in (H). n = 6 biological replicates. ( I – K ) Representative flow cytometry plots of CD45 − Ter119 − CD31 − leptin receptor + (LepR + ) mesenchymal stem cells (MSCs) in the bone marrow at 4 weeks (I), with analysis of the proportion of SA-β-Gal–positive cells (J) and corresponding quantification (K). n = 6 biological replicates. ( L ) Representative flow cytometry plots of CD45 − Ter119 − CD144 + cells (including endothelial cells and endothelial progenitors) in the bone marrow at week 4 post-MPS treatment. ( M and N ) Gating and analysis of CD45 − Ter119 − CD144 + HMGB1 + ECs by flow cytometry (M), and corresponding quantification (N). n = 6 biological replicates. ( O and P ) Representative immunofluorescence images showing OPN + osteoblasts and γ-H2A.X + DNA damage marker–positive cells in the femur at 4 weeks (O), with quantification of senescent osteoblasts (P). n = 6 biological replicates. (Scale bars, 100 μm and 50 μm) Data are presented as mean ± SD. ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Statistical significance was determined using an unpaired two-tailed Student's t -test ( D, E, H, K, N and P ).

    Journal: Bioactive Materials

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    doi: 10.1016/j.bioactmat.2025.11.039

    Figure Lengend Snippet: SCS attenuates full-blown bone marrow senescence during GC-induced skeletal degeneration. ( A ) Schematic illustration of the experimental design for assessing bone marrow senescence at 4 weeks after combined SCS and MPS treatment. ( B ) Representative images of SA-β-Gal–positive cells (green) in femur after MPS treatment. BM indicates bone marrow; TBM indicates trabecular bone matrix. (Scale bars, 100 μm and 25 μm) ( C – E ) Representative immunofluorescence images at week 4 showing Emcn + sinusoidal ECs, ALP + osteoblasts, and p16 + senescent cells (C), with corresponding quantification of Emcn + p16 + (D) and ALP + p16 + cells (E). n = 6 biological replicates. (Scale bars, 100 μm and 50 μm) ( F – H ) Flow cytometry analysis of CD45 − Ter119 − CD31 + arteriolar ECs in the femur after PBS or SCS treatment (F). Ki-67 + proliferative status was further analyzed within this population (G), and corresponding double-positive cell quantification is shown in (H). n = 6 biological replicates. ( I – K ) Representative flow cytometry plots of CD45 − Ter119 − CD31 − leptin receptor + (LepR + ) mesenchymal stem cells (MSCs) in the bone marrow at 4 weeks (I), with analysis of the proportion of SA-β-Gal–positive cells (J) and corresponding quantification (K). n = 6 biological replicates. ( L ) Representative flow cytometry plots of CD45 − Ter119 − CD144 + cells (including endothelial cells and endothelial progenitors) in the bone marrow at week 4 post-MPS treatment. ( M and N ) Gating and analysis of CD45 − Ter119 − CD144 + HMGB1 + ECs by flow cytometry (M), and corresponding quantification (N). n = 6 biological replicates. ( O and P ) Representative immunofluorescence images showing OPN + osteoblasts and γ-H2A.X + DNA damage marker–positive cells in the femur at 4 weeks (O), with quantification of senescent osteoblasts (P). n = 6 biological replicates. (Scale bars, 100 μm and 50 μm) Data are presented as mean ± SD. ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Statistical significance was determined using an unpaired two-tailed Student's t -test ( D, E, H, K, N and P ).

    Article Snippet: Following washing with buffer, cells were incubated with APC streptavidin at 4 °C for 40 min. After washing, CD45 − Ter119 − CD31 − LepR + MSCs were sorted using the MACSQuant® Tyto® cell sorter (Miltenyi Biotec).

    Techniques: Immunofluorescence, Flow Cytometry, Marker, Two Tailed Test

    SCS suppresses senescence cascade amplification by attenuating secondary spread from GC-induced primary senescent adipocytes. ( A ) Schematic illustration of SCS intervention exclusively during the fully developed senescent phase of MPS-induced bone marrow. ( B ) qPCR analysis of senescence-associated markers ( Cdkn1b , Cdkn1a , and Cdkn2c ) in bone tissues at 4 weeks following combined SCS and MPS treatment. n = 3 biological replicates. ( C ) ELISA analysis of bone marrow senescence-associated factors (IL-1β, IL-18, TNF-α, IL-6, CXCL1, and CCL3) after 4 weeks of combined treatment with SCS and MPS. n = 4 biological replicates. ( D ) Quantification of the maximal compressive load of the isolated distal femur and femoral diaphysis. n = 6 biological replicates. ( E ) Schematic diagram depicting isolation of bone marrow adipocytes from mice treated with SCS and MPS for 14 days using mature adipocyte-specific fast centrifugation and construction of a senescence propagation model in vitro . ( F and G ) Representative flow cytometry plots (D) and quantification (E) of EdU-positive (proliferating) CD45 − Ter119 − CD31 − LepR + MSCs cultured for 3 days with adipocyte conditioned medium (CM). n = 6 biological replicates. ( H and I ) Representative ALP staining images (F) and corresponding quantification of ALP activity (G) in CD45 − Ter119 − CD31 − LepR + MSCs cultured with SCS-induced adipocyte CM. n = 6 biological replicates. (Scale bars, 50 μm and 30 μm) ( J and K ) Representative Oil Red O staining (H) and quantification (I) of adipogenic differentiation in MSCs cultured with SCS-induced adipocyte CM. n = 6 biological replicates. (Scale bars, 50 μm and 25 μm) ( L and M ) Representative images (J) and quantification (K) of crystal violet-stained fibroblast colony-forming units (CFU-F) in MSCs cultured with various adipocyte CMs. n = 6 biological replicates. (Scale bars, 400 μm) ( N ) qPCR analysis of senescence-related markers ( Cdkn2a and Cdkn1a ) in MSCs treated with different adipocyte CMs. n = 3 biological replicates. ( O and P ) Representative immunofluorescence-FISH images (M) and quantification (N) showing colocalization of γ-H2A.X with telomere-associated foci (TAF) in MSCs cultured with different adipocyte CMs. n = 6 biological replicates. (Scale bars, 7 μm and 1 μm) ( Q and R ) Representative images (O) and quantification (P) of 2D tube formation assays in HUVECs cultured for 3 days with various adipocyte CMs. n = 6 biological replicates. (Scale bars, 100 μm and 25 μm) ( S and T ) Representative images (Q) and quantification (R) of SA-β-Gal–positive HUVECs (green) following 3-day treatment with different adipocyte CMs. n = 6 biological replicates. (Scale bars, 100 μm and 25 μm) ( U ) qPCR analysis of the senescence-related gene LMNB1 in HUVECs treated with various adipocyte CMs. n = 3 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using an unpaired two-tailed Student's t -test ( B, C, D, G, I, K, M, N, R, T and U ).

    Journal: Bioactive Materials

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    doi: 10.1016/j.bioactmat.2025.11.039

    Figure Lengend Snippet: SCS suppresses senescence cascade amplification by attenuating secondary spread from GC-induced primary senescent adipocytes. ( A ) Schematic illustration of SCS intervention exclusively during the fully developed senescent phase of MPS-induced bone marrow. ( B ) qPCR analysis of senescence-associated markers ( Cdkn1b , Cdkn1a , and Cdkn2c ) in bone tissues at 4 weeks following combined SCS and MPS treatment. n = 3 biological replicates. ( C ) ELISA analysis of bone marrow senescence-associated factors (IL-1β, IL-18, TNF-α, IL-6, CXCL1, and CCL3) after 4 weeks of combined treatment with SCS and MPS. n = 4 biological replicates. ( D ) Quantification of the maximal compressive load of the isolated distal femur and femoral diaphysis. n = 6 biological replicates. ( E ) Schematic diagram depicting isolation of bone marrow adipocytes from mice treated with SCS and MPS for 14 days using mature adipocyte-specific fast centrifugation and construction of a senescence propagation model in vitro . ( F and G ) Representative flow cytometry plots (D) and quantification (E) of EdU-positive (proliferating) CD45 − Ter119 − CD31 − LepR + MSCs cultured for 3 days with adipocyte conditioned medium (CM). n = 6 biological replicates. ( H and I ) Representative ALP staining images (F) and corresponding quantification of ALP activity (G) in CD45 − Ter119 − CD31 − LepR + MSCs cultured with SCS-induced adipocyte CM. n = 6 biological replicates. (Scale bars, 50 μm and 30 μm) ( J and K ) Representative Oil Red O staining (H) and quantification (I) of adipogenic differentiation in MSCs cultured with SCS-induced adipocyte CM. n = 6 biological replicates. (Scale bars, 50 μm and 25 μm) ( L and M ) Representative images (J) and quantification (K) of crystal violet-stained fibroblast colony-forming units (CFU-F) in MSCs cultured with various adipocyte CMs. n = 6 biological replicates. (Scale bars, 400 μm) ( N ) qPCR analysis of senescence-related markers ( Cdkn2a and Cdkn1a ) in MSCs treated with different adipocyte CMs. n = 3 biological replicates. ( O and P ) Representative immunofluorescence-FISH images (M) and quantification (N) showing colocalization of γ-H2A.X with telomere-associated foci (TAF) in MSCs cultured with different adipocyte CMs. n = 6 biological replicates. (Scale bars, 7 μm and 1 μm) ( Q and R ) Representative images (O) and quantification (P) of 2D tube formation assays in HUVECs cultured for 3 days with various adipocyte CMs. n = 6 biological replicates. (Scale bars, 100 μm and 25 μm) ( S and T ) Representative images (Q) and quantification (R) of SA-β-Gal–positive HUVECs (green) following 3-day treatment with different adipocyte CMs. n = 6 biological replicates. (Scale bars, 100 μm and 25 μm) ( U ) qPCR analysis of the senescence-related gene LMNB1 in HUVECs treated with various adipocyte CMs. n = 3 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using an unpaired two-tailed Student's t -test ( B, C, D, G, I, K, M, N, R, T and U ).

    Article Snippet: Following washing with buffer, cells were incubated with APC streptavidin at 4 °C for 40 min. After washing, CD45 − Ter119 − CD31 − LepR + MSCs were sorted using the MACSQuant® Tyto® cell sorter (Miltenyi Biotec).

    Techniques: Amplification, Enzyme-linked Immunosorbent Assay, Isolation, Centrifugation, In Vitro, Flow Cytometry, Cell Culture, Staining, Activity Assay, Immunofluorescence, Two Tailed Test

    SCS reprograms the lineage commitment of MSCs after GC treatment and inhibits the generation of primary senescent adipocytes. ( A ) Schematic illustration of the in vitro investigation of SCS targeting the prostaglandin/PPARγ/INK positive feedback loop in MPS-induced primary senescent adipocytes. ( B ) Representative flow cytometry plot showing p16 + senescent cells in adipocytes derived from bone marrow after 14 days of in vivo MPS induction and subsequently treated with SCS in vitro . ( C ) qPCR analysis of 12 senescence-associated markers in primary senescent adipocytes after in vitro SCS treatment. n = 3 biological replicates. ( D ) ELISA analysis of IL-1β levels in adipocyte supernatant following in vitro SCS treatment. n = 6 biological replicates. ( E ) ELISA analysis of secreted prostaglandins PGD2 and PGE2 in adipocytes under different treatment conditions. D-PBS: bone marrow adipocytes isolated from mice treated in vivo with the solvent control DMSO, followed by in vitro treatment with PBS; M-PBS: bone marrow adipocytes isolated from mice treated in vivo with MPS, followed by in vitro treatment with PBS. M-SCS: bone marrow adipocytes isolated from mice treated in vivo with MPS, followed by in vitro treatment with SCS. ( F ) Western blot analysis of intracellular COX-2 protein levels in adipocytes across the three treatment conditions. ( G ) Schematic illustration of competitive osteogenic–adipogenic differentiation of CD45 − Ter119 − CD31 − LepR + MSCs after 7 days of in vivo SCS and MPS co-treatment. ( H ) qPCR analysis of pan-adipocyte markers ( Fabp4 , Adipoq , Plin1 , Cd36 , and Lep ) in CD45 − Ter119 − CD31 − LepR + MSCs after 14 days of in vitro competitive lineage differentiation. n = 3 biological replicates. ( I and J ) Representative immunofluorescence images (I) and quantification (J) of perilipin + adipocytes and osteopontin + mature osteoblasts derived from lineage-committed MSCs. n = 6 biological replicates. (Scale bars, 30 μm, 15 μm and 15 μm). ( K ) Western blot analysis of adipogenesis-related markers C/EBPα, PPARγ, and C/EBPβ in the lineage-mixed cells after in vitro competitive differentiation of CD45 − Ter119 − CD31 − LepR + MSCs. ( L ) qPCR analysis of lipogenesis-related markers Fasn , Scd1 , Srebf1 , Acaca , and Acacb . n = 3 biological replicates. ( M and N ) Representative H&E staining images (M) of the femurs at day 14 following SCS and MPS co-treatment. Yellow arrows indicate bone marrow adipocytes. Magnified images show hypertrophic adipocyte morphology, with quantification of adipocyte diameter (N). n = 19 biological replicates. (Scale bars, 200 μm, 50 μm and 20 μm). Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using an unpaired two-tailed Student's t -test ( C, D, H, J, L and N ), or one-way ANOVA with Tukey's post hoc test ( E ).

    Journal: Bioactive Materials

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    doi: 10.1016/j.bioactmat.2025.11.039

    Figure Lengend Snippet: SCS reprograms the lineage commitment of MSCs after GC treatment and inhibits the generation of primary senescent adipocytes. ( A ) Schematic illustration of the in vitro investigation of SCS targeting the prostaglandin/PPARγ/INK positive feedback loop in MPS-induced primary senescent adipocytes. ( B ) Representative flow cytometry plot showing p16 + senescent cells in adipocytes derived from bone marrow after 14 days of in vivo MPS induction and subsequently treated with SCS in vitro . ( C ) qPCR analysis of 12 senescence-associated markers in primary senescent adipocytes after in vitro SCS treatment. n = 3 biological replicates. ( D ) ELISA analysis of IL-1β levels in adipocyte supernatant following in vitro SCS treatment. n = 6 biological replicates. ( E ) ELISA analysis of secreted prostaglandins PGD2 and PGE2 in adipocytes under different treatment conditions. D-PBS: bone marrow adipocytes isolated from mice treated in vivo with the solvent control DMSO, followed by in vitro treatment with PBS; M-PBS: bone marrow adipocytes isolated from mice treated in vivo with MPS, followed by in vitro treatment with PBS. M-SCS: bone marrow adipocytes isolated from mice treated in vivo with MPS, followed by in vitro treatment with SCS. ( F ) Western blot analysis of intracellular COX-2 protein levels in adipocytes across the three treatment conditions. ( G ) Schematic illustration of competitive osteogenic–adipogenic differentiation of CD45 − Ter119 − CD31 − LepR + MSCs after 7 days of in vivo SCS and MPS co-treatment. ( H ) qPCR analysis of pan-adipocyte markers ( Fabp4 , Adipoq , Plin1 , Cd36 , and Lep ) in CD45 − Ter119 − CD31 − LepR + MSCs after 14 days of in vitro competitive lineage differentiation. n = 3 biological replicates. ( I and J ) Representative immunofluorescence images (I) and quantification (J) of perilipin + adipocytes and osteopontin + mature osteoblasts derived from lineage-committed MSCs. n = 6 biological replicates. (Scale bars, 30 μm, 15 μm and 15 μm). ( K ) Western blot analysis of adipogenesis-related markers C/EBPα, PPARγ, and C/EBPβ in the lineage-mixed cells after in vitro competitive differentiation of CD45 − Ter119 − CD31 − LepR + MSCs. ( L ) qPCR analysis of lipogenesis-related markers Fasn , Scd1 , Srebf1 , Acaca , and Acacb . n = 3 biological replicates. ( M and N ) Representative H&E staining images (M) of the femurs at day 14 following SCS and MPS co-treatment. Yellow arrows indicate bone marrow adipocytes. Magnified images show hypertrophic adipocyte morphology, with quantification of adipocyte diameter (N). n = 19 biological replicates. (Scale bars, 200 μm, 50 μm and 20 μm). Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using an unpaired two-tailed Student's t -test ( C, D, H, J, L and N ), or one-way ANOVA with Tukey's post hoc test ( E ).

    Article Snippet: Following washing with buffer, cells were incubated with APC streptavidin at 4 °C for 40 min. After washing, CD45 − Ter119 − CD31 − LepR + MSCs were sorted using the MACSQuant® Tyto® cell sorter (Miltenyi Biotec).

    Techniques: In Vitro, Flow Cytometry, Derivative Assay, In Vivo, Enzyme-linked Immunosorbent Assay, Isolation, Solvent, Control, Western Blot, Immunofluorescence, Staining, Two Tailed Test

    Gene expression profiles of bone marrow-derived LepR + MSCs after 7-day in vivo co-treatment with SCS and MPS. ( A ) Heatmap showing DEGs in CD45 − Ter119 − CD31 − LepR + MSCs sorted from bone marrow at day 7 post-treatment with SCS versus PBS ( P < 0.05, |log fold change| > 1.5). n = 3 biological replicates. ( B ) Representative GO biological process enrichment analysis of downregulated DEGs. ( C ) Top 20 enriched KEGG pathways of downregulated DEGs in SCS versus PBS. ( D ) GSEA plots of biological processes positively enriched in the SCS group (|NES| > 1, nominal P < 0.05, FDR <0.25). ( E ) Representative downregulated DEGs associated with adipogenesis and lipogenesis identified through KEGG pathway analysis. n = 3 biological replicates. ( F ) Top 20 enriched KEGG pathways of upregulated DEGs in SCS versus PBS. ( G ) Representative GO biological process enrichment analysis of upregulated DEGs. ( H ) Representative upregulated DEGs identified through biological process enrichment analysis. n = 3 biological replicates. ( I and J ) GSEA plots of KEGG pathways negatively enriched in the SCS group (|NES| > 1, nominal P < 0.05, FDR <0.25).

    Journal: Bioactive Materials

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    doi: 10.1016/j.bioactmat.2025.11.039

    Figure Lengend Snippet: Gene expression profiles of bone marrow-derived LepR + MSCs after 7-day in vivo co-treatment with SCS and MPS. ( A ) Heatmap showing DEGs in CD45 − Ter119 − CD31 − LepR + MSCs sorted from bone marrow at day 7 post-treatment with SCS versus PBS ( P < 0.05, |log fold change| > 1.5). n = 3 biological replicates. ( B ) Representative GO biological process enrichment analysis of downregulated DEGs. ( C ) Top 20 enriched KEGG pathways of downregulated DEGs in SCS versus PBS. ( D ) GSEA plots of biological processes positively enriched in the SCS group (|NES| > 1, nominal P < 0.05, FDR <0.25). ( E ) Representative downregulated DEGs associated with adipogenesis and lipogenesis identified through KEGG pathway analysis. n = 3 biological replicates. ( F ) Top 20 enriched KEGG pathways of upregulated DEGs in SCS versus PBS. ( G ) Representative GO biological process enrichment analysis of upregulated DEGs. ( H ) Representative upregulated DEGs identified through biological process enrichment analysis. n = 3 biological replicates. ( I and J ) GSEA plots of KEGG pathways negatively enriched in the SCS group (|NES| > 1, nominal P < 0.05, FDR <0.25).

    Article Snippet: Following washing with buffer, cells were incubated with APC streptavidin at 4 °C for 40 min. After washing, CD45 − Ter119 − CD31 − LepR + MSCs were sorted using the MACSQuant® Tyto® cell sorter (Miltenyi Biotec).

    Techniques: Gene Expression, Derivative Assay, In Vivo

    SCS targets downstream senescent lineage commitment of bone marrow MSCs to mitigate GC-induced bone deterioration. ( A ) Schematic diagram illustrating the experimental design: CD45 − Ter119 − CD31 − LepR + MSCs isolated from mice co-treated with SCS and MPS for 7 days were subjected to in vitro lineage-competitive differentiation, followed by DEX-induced senescence in lineage-mixed cells. These cells were then adoptively transplanted into healthy bone marrow cavity to assess bone deterioration development. ( B ) Representative H&E-stained images of the femur 12 weeks after adoptive transfer. PBS-DEX group: LepR + MSCs from PBS and MPS co-treated mice subjected to in vitro lineage differentiation and DEX-induced senescence, followed by transplantation. SCS-DEX group: LepR + MSCs from SCS and MPS co-treated mice processed similarly. PBS group: solvent control without cell transplantation. Solid arrows indicate intact osteocytes; hollow arrows indicate empty lacunae. (Scale bars, 250 μm and 25 μm) ( C – E ) Quantitative analysis of marrow hypertrophic adipocyte diameter (C), proportion of empty osteocyte lacunae in trabecular bone (D), and adipocyte number (E) in the metaphysis 12 weeks post-transplantation. n = 19 biological replicates (C), n = 6 biological replicates (D), n = 8 biological replicates (E). ( F ) Quantification of empty lacunae in epiphysis at 12 weeks post-transplantation. n = 6 biological replicates. ( G – I ) Representative flow cytometry plots of capillary ECs subtypes in the femur at 12 weeks (G), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (H) and CD45 − Ter119 − CD31 lo Emcn lo ECs (I). n = 6 biological replicates. ( J and K ) Representative flow cytometry plots (J) and corresponding quantification (K) of CD45 − Ter119 − Sca-1 hi CD31 hi arteriolar ECs in the femur at 12 weeks post-transplantation. n = 6 biological replicates. ( L ) Representative micro-CT images of the femur at 12 weeks post-transplantation across different treatment groups. (Scale bars, 1.5 mm and 500 μm) ( M – P ) Quantitative analysis of bone parameters in the metaphysis: bone mineral density (BMD) (M), percent bone volume (BV/TV) (N), trabecular separation (Tb.Sp) (O), and trabecular number (Tb.N) (P). n = 6 biological replicates. ( Q ) Serum ELISA analysis of the osteogenic marker osteocalcin at 12 weeks post-transplantation. n = 6 biological replicates. ( R and S ) ELISA analysis of PDGF-BB (R) and VEGF (S) in both bone marrow supernatant and peripheral serum at 12 weeks post-transplantation. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, E, F, H, I, K, M, N, O, P, Q, R and S ).

    Journal: Bioactive Materials

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    doi: 10.1016/j.bioactmat.2025.11.039

    Figure Lengend Snippet: SCS targets downstream senescent lineage commitment of bone marrow MSCs to mitigate GC-induced bone deterioration. ( A ) Schematic diagram illustrating the experimental design: CD45 − Ter119 − CD31 − LepR + MSCs isolated from mice co-treated with SCS and MPS for 7 days were subjected to in vitro lineage-competitive differentiation, followed by DEX-induced senescence in lineage-mixed cells. These cells were then adoptively transplanted into healthy bone marrow cavity to assess bone deterioration development. ( B ) Representative H&E-stained images of the femur 12 weeks after adoptive transfer. PBS-DEX group: LepR + MSCs from PBS and MPS co-treated mice subjected to in vitro lineage differentiation and DEX-induced senescence, followed by transplantation. SCS-DEX group: LepR + MSCs from SCS and MPS co-treated mice processed similarly. PBS group: solvent control without cell transplantation. Solid arrows indicate intact osteocytes; hollow arrows indicate empty lacunae. (Scale bars, 250 μm and 25 μm) ( C – E ) Quantitative analysis of marrow hypertrophic adipocyte diameter (C), proportion of empty osteocyte lacunae in trabecular bone (D), and adipocyte number (E) in the metaphysis 12 weeks post-transplantation. n = 19 biological replicates (C), n = 6 biological replicates (D), n = 8 biological replicates (E). ( F ) Quantification of empty lacunae in epiphysis at 12 weeks post-transplantation. n = 6 biological replicates. ( G – I ) Representative flow cytometry plots of capillary ECs subtypes in the femur at 12 weeks (G), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (H) and CD45 − Ter119 − CD31 lo Emcn lo ECs (I). n = 6 biological replicates. ( J and K ) Representative flow cytometry plots (J) and corresponding quantification (K) of CD45 − Ter119 − Sca-1 hi CD31 hi arteriolar ECs in the femur at 12 weeks post-transplantation. n = 6 biological replicates. ( L ) Representative micro-CT images of the femur at 12 weeks post-transplantation across different treatment groups. (Scale bars, 1.5 mm and 500 μm) ( M – P ) Quantitative analysis of bone parameters in the metaphysis: bone mineral density (BMD) (M), percent bone volume (BV/TV) (N), trabecular separation (Tb.Sp) (O), and trabecular number (Tb.N) (P). n = 6 biological replicates. ( Q ) Serum ELISA analysis of the osteogenic marker osteocalcin at 12 weeks post-transplantation. n = 6 biological replicates. ( R and S ) ELISA analysis of PDGF-BB (R) and VEGF (S) in both bone marrow supernatant and peripheral serum at 12 weeks post-transplantation. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, E, F, H, I, K, M, N, O, P, Q, R and S ).

    Article Snippet: Following washing with buffer, cells were incubated with APC streptavidin at 4 °C for 40 min. After washing, CD45 − Ter119 − CD31 − LepR + MSCs were sorted using the MACSQuant® Tyto® cell sorter (Miltenyi Biotec).

    Techniques: Isolation, In Vitro, Staining, Adoptive Transfer Assay, Transplantation Assay, Solvent, Control, Flow Cytometry, Micro-CT, Enzyme-linked Immunosorbent Assay, Marker

    SCS modulates mesenchymal stem cell lineage bias via activation of the IGF-1/PI3K/Akt/mTOR signaling pathway. ( A ) Quantitative analysis of osteocyte morphology in the trabecular bone matrix of the bone marrow at week 6 after MPS treatment with or without SCS, in the presence of various neutralizing antibodies (NAbs) and antagonistic proteins. ( B ) ELISA analysis of IGF-1 and BMP-2 levels in the femoral bone marrow and peripheral serum at day 7 following SCS treatment under MPS conditions. ( C and D ) Western blot analysis of phospho-PI3K, phospho-Akt, and phospho-mTOR (C), as well as phospho-Smad1/5/8, phospho-ERK, and phospho-p38 (D), in CD45 − Ter119 − CD31 − LepR + MSCs after 15-min stimulation with conditioned medium (CM) derived from bone marrow fluid at day 7 following SCS treatment. ( E – G ) Representative flow cytometry plots (E, F) and quantitative analysis (G) of CD45 − CD31 − Sca-1 + CD24 − adipocyte progenitor cells (APCs), CD45 − CD31 − Sca-1 + CD24 + MSCs (E), and CD45 − CD31 − Sca-1 − PDGFRα + (Pα + ) osteoprogenitor cells (OPCs) (F) from femoral bone marrow at day 14 post-MPS induction with or without combined treatment using SCS and IGF-1 NAb or Noggin. ( H and I ) Representative SA-β-Gal staining images (green) of the femur (H), and corresponding quantification (I), at week 4 following MPS treatment with SCS in combination with IGF-1 NAb or DMH1. Insets show magnified views of bone marrow (BM) and trabecular bone matrix (TBM) regions. (Scale bars, 100 μm and 25 μm) ( J ) qPCR analysis of 12 senescence-associated markers in ex vivo femoral bone tissues at week 4 following MPS treatment with SCS in combination with IGF-1 NAb or DMH1. ( K ) Representative Oil Red O staining images of CD45 − Ter119 − CD31 − LepR + MSCs sorted from femurs at day 7 following MPS treatment with SCS in combination with LY294002 or LDN-193189, after in vitro adipogenic induction. (Scale bars, 50 μm and 25 μm) ( L and M ) γ-H2A.X and telomere-associated DNA damage foci (TAFs) co-localization analysis (L), and corresponding quantification (M), in CD45 − Ter119 − CD31 + arteriolar ECs sorted from femurs at day 28 following MPS treatment with SCS in combination with rapamycin or LDN-193189, using immuno-FISH staining. (Scale bars, 7 μm and 1 μm) ( N and O ) Sequential fluorescent labeling using calcein (N) and quantification of mineral apposition rate (O) in femurs treated with SCS and MPS for 4 weeks, with or without LY294002 and/or GW9662. (Scale bars, 50 μm) ( P ) ELISA analysis of five senescence-associated cytokines in femoral bone marrow at day 28 following MPS treatment with SCS in combination with rapamycin and/or T0070907. ( Q and R ) Representative t-distributed stochastic neighbor embedding (t-SNE) plots (Q) from flow cytometric analysis of CD45 − CD31 − Sca-1 + CD24 − APCs, CD45 − CD31 − Sca-1 + CD24 + MSCs, CD45 − CD31 − Sca-1 − Pα + OPCs, CD45 − Ter119 − CD31 + arteriolar ECs, and CD45 − Ter119 − Emcn + sinusoidal ECs at day 14 following MPS treatment with SCS in combination with IGF-1 and/or rosiglitazone, and quantitative analysis of APCs (R) ( S ) Heatmap showing the fluorescent intensity distribution of Lamin-B1 expression across five cellular subpopulations as identified in the t-SNE clustering plot. ∗ P < 0.05 vs. IgG (empty lacunae); # P < 0.05 vs. IgG (filled lacunae). ∗ P < 0.05 vs. SCS; # P < 0.05 vs. SCS + IGF-1 NAb. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using an unpaired two-tailed Student's t -test ( B ), or one-way ANOVA with Tukey's post hoc test ( A, G, I, J, O, P and R ).

    Journal: Bioactive Materials

    Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

    doi: 10.1016/j.bioactmat.2025.11.039

    Figure Lengend Snippet: SCS modulates mesenchymal stem cell lineage bias via activation of the IGF-1/PI3K/Akt/mTOR signaling pathway. ( A ) Quantitative analysis of osteocyte morphology in the trabecular bone matrix of the bone marrow at week 6 after MPS treatment with or without SCS, in the presence of various neutralizing antibodies (NAbs) and antagonistic proteins. ( B ) ELISA analysis of IGF-1 and BMP-2 levels in the femoral bone marrow and peripheral serum at day 7 following SCS treatment under MPS conditions. ( C and D ) Western blot analysis of phospho-PI3K, phospho-Akt, and phospho-mTOR (C), as well as phospho-Smad1/5/8, phospho-ERK, and phospho-p38 (D), in CD45 − Ter119 − CD31 − LepR + MSCs after 15-min stimulation with conditioned medium (CM) derived from bone marrow fluid at day 7 following SCS treatment. ( E – G ) Representative flow cytometry plots (E, F) and quantitative analysis (G) of CD45 − CD31 − Sca-1 + CD24 − adipocyte progenitor cells (APCs), CD45 − CD31 − Sca-1 + CD24 + MSCs (E), and CD45 − CD31 − Sca-1 − PDGFRα + (Pα + ) osteoprogenitor cells (OPCs) (F) from femoral bone marrow at day 14 post-MPS induction with or without combined treatment using SCS and IGF-1 NAb or Noggin. ( H and I ) Representative SA-β-Gal staining images (green) of the femur (H), and corresponding quantification (I), at week 4 following MPS treatment with SCS in combination with IGF-1 NAb or DMH1. Insets show magnified views of bone marrow (BM) and trabecular bone matrix (TBM) regions. (Scale bars, 100 μm and 25 μm) ( J ) qPCR analysis of 12 senescence-associated markers in ex vivo femoral bone tissues at week 4 following MPS treatment with SCS in combination with IGF-1 NAb or DMH1. ( K ) Representative Oil Red O staining images of CD45 − Ter119 − CD31 − LepR + MSCs sorted from femurs at day 7 following MPS treatment with SCS in combination with LY294002 or LDN-193189, after in vitro adipogenic induction. (Scale bars, 50 μm and 25 μm) ( L and M ) γ-H2A.X and telomere-associated DNA damage foci (TAFs) co-localization analysis (L), and corresponding quantification (M), in CD45 − Ter119 − CD31 + arteriolar ECs sorted from femurs at day 28 following MPS treatment with SCS in combination with rapamycin or LDN-193189, using immuno-FISH staining. (Scale bars, 7 μm and 1 μm) ( N and O ) Sequential fluorescent labeling using calcein (N) and quantification of mineral apposition rate (O) in femurs treated with SCS and MPS for 4 weeks, with or without LY294002 and/or GW9662. (Scale bars, 50 μm) ( P ) ELISA analysis of five senescence-associated cytokines in femoral bone marrow at day 28 following MPS treatment with SCS in combination with rapamycin and/or T0070907. ( Q and R ) Representative t-distributed stochastic neighbor embedding (t-SNE) plots (Q) from flow cytometric analysis of CD45 − CD31 − Sca-1 + CD24 − APCs, CD45 − CD31 − Sca-1 + CD24 + MSCs, CD45 − CD31 − Sca-1 − Pα + OPCs, CD45 − Ter119 − CD31 + arteriolar ECs, and CD45 − Ter119 − Emcn + sinusoidal ECs at day 14 following MPS treatment with SCS in combination with IGF-1 and/or rosiglitazone, and quantitative analysis of APCs (R) ( S ) Heatmap showing the fluorescent intensity distribution of Lamin-B1 expression across five cellular subpopulations as identified in the t-SNE clustering plot. ∗ P < 0.05 vs. IgG (empty lacunae); # P < 0.05 vs. IgG (filled lacunae). ∗ P < 0.05 vs. SCS; # P < 0.05 vs. SCS + IGF-1 NAb. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using an unpaired two-tailed Student's t -test ( B ), or one-way ANOVA with Tukey's post hoc test ( A, G, I, J, O, P and R ).

    Article Snippet: Following washing with buffer, cells were incubated with APC streptavidin at 4 °C for 40 min. After washing, CD45 − Ter119 − CD31 − LepR + MSCs were sorted using the MACSQuant® Tyto® cell sorter (Miltenyi Biotec).

    Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Derivative Assay, Flow Cytometry, Staining, Ex Vivo, In Vitro, Labeling, Expressing, Two Tailed Test

    (A) Workflow illustrating circadian phase inference and rhythmic gene identification in human TNBC single-cell RNA-seq data using CYCLOPS2.0 and DiscoRhythm. (B) Left: Stacked bar plots showing relative proportions of immune cell populations across predicted circadian phases within the human TNBC tumor microenvironment (TME). Right: Line plots showing circadian fitting curves of myeloid (top) and CD8⁺ T cell (bottom) fractions across a circadian day. Points indicate mean values at each time point (± SEM). Gray shading denotes the dark phase (CT12–CT24/CT0). p values indicate rhythmicity assessed by cosinor regression. n = 10-13 patient samples per time point. (C) Heatmap showing rhythmic expression patterns of circadian genes in CD4⁺ T cells across inferred circadian phases. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (D) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in CD4⁺ T cells, including interferon signaling and T cell activation. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (E) Circadian fitting curves of representative genes ( STAT3 and BCL6 ) in CD4⁺ T cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (F) Heatmap showing rhythmic expression patterns of circadian genes in CD8⁺ T cells across inferred circadian time points. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (G) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in CD8⁺ T cells, including interferon signaling and T cell activation. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (H) Circadian fitting curves of representative genes ( STAT3 and BCL6 ) in CD8⁺ T cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (I) Heatmap showing rhythmic expression patterns of circadian genes in myeloid cells across inferred circadian time points. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (J) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in myeloid cells, including regulation of phagocytosis and type II interferon signaling. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (K) Circadian fitting curves of representative genes ( SYK and STAT1 ) in myeloid cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (L) Circadian fitting curves illustrating the temporal mismatch between antigen processing and presentation in myeloid cells and T cell recognition programs in CD4⁺ and CD8⁺ T cells. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile). Vertical dashed lines indicate the peak timing of each functional program. The gray area indicates the dark phase (CT12–CT24/CT0). (M) Circadian expression profiles of representative genes involved in antigen presentation ( CIITA , HLA-A ) in myeloid cells and T cell recognition ( CD3D , TRAV35 ) in CD4⁺ and CD8⁺ T cells. Points represent mean expression values at each inferred circadian time point, with error bars indicating SEM. The gray area indicates the dark phase (CT12–CT24/CT0).

    Journal: bioRxiv

    Article Title: Circadian misalignment underlies immune escape in breast cancer

    doi: 10.64898/2026.05.26.726543

    Figure Lengend Snippet: (A) Workflow illustrating circadian phase inference and rhythmic gene identification in human TNBC single-cell RNA-seq data using CYCLOPS2.0 and DiscoRhythm. (B) Left: Stacked bar plots showing relative proportions of immune cell populations across predicted circadian phases within the human TNBC tumor microenvironment (TME). Right: Line plots showing circadian fitting curves of myeloid (top) and CD8⁺ T cell (bottom) fractions across a circadian day. Points indicate mean values at each time point (± SEM). Gray shading denotes the dark phase (CT12–CT24/CT0). p values indicate rhythmicity assessed by cosinor regression. n = 10-13 patient samples per time point. (C) Heatmap showing rhythmic expression patterns of circadian genes in CD4⁺ T cells across inferred circadian phases. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (D) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in CD4⁺ T cells, including interferon signaling and T cell activation. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (E) Circadian fitting curves of representative genes ( STAT3 and BCL6 ) in CD4⁺ T cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (F) Heatmap showing rhythmic expression patterns of circadian genes in CD8⁺ T cells across inferred circadian time points. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (G) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in CD8⁺ T cells, including interferon signaling and T cell activation. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (H) Circadian fitting curves of representative genes ( STAT3 and BCL6 ) in CD8⁺ T cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (I) Heatmap showing rhythmic expression patterns of circadian genes in myeloid cells across inferred circadian time points. The color bar reflects the expression level from high (bright yellow) to low (deep purple). (J) Circadian fitting curves showing the rhythmic dynamics of representative functional pathways in myeloid cells, including regulation of phagocytosis and type II interferon signaling. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile), and the gray area indicates the dark phase (CT12–CT24/CT0). (K) Circadian fitting curves of representative genes ( SYK and STAT1 ) in myeloid cells. Solid lines indicate human TNBC data, and dashed lines indicate the corresponding mouse tumor data. The gray area indicates the dark phase (CT12–CT24/CT0). (L) Circadian fitting curves illustrating the temporal mismatch between antigen processing and presentation in myeloid cells and T cell recognition programs in CD4⁺ and CD8⁺ T cells. Bold lines represent mean fitted curves across genes within each pathway, shaded areas indicate the interquartile range (25th–75th percentile). Vertical dashed lines indicate the peak timing of each functional program. The gray area indicates the dark phase (CT12–CT24/CT0). (M) Circadian expression profiles of representative genes involved in antigen presentation ( CIITA , HLA-A ) in myeloid cells and T cell recognition ( CD3D , TRAV35 ) in CD4⁺ and CD8⁺ T cells. Points represent mean expression values at each inferred circadian time point, with error bars indicating SEM. The gray area indicates the dark phase (CT12–CT24/CT0).

    Article Snippet: After neutralization and additional washes, single-cell suspensions were incubated with CD45 MicroBeads (Miltenyi Biotec, #130-052-301) according to the manufacturer’s protocol.

    Techniques: Single Cell, RNA Sequencing, Expressing, Functional Assay, Activation Assay, Immunopeptidomics